{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Impaired+Glucose+Metabolism&page=2",
    "query": {
      "condition": "Impaired Glucose Metabolism",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Impaired+Glucose+Metabolism&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T02:48:10.883Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01478399",
      "title": "Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "PB1023 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PhaseBio Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 16,
      "start_date": "2011-12",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2013-04-15",
      "last_synced_at": "2026-07-24T02:48:10.883Z",
      "location_count": 2,
      "location_summary": "Saint Paul, Minnesota • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01478399"
    },
    {
      "nct_id": "NCT00312130",
      "title": "A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pre-diabetes"
      ],
      "interventions": [
        {
          "name": "Vildagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2005-04",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2016-11-18",
      "last_synced_at": "2026-07-24T02:48:10.883Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00312130"
    },
    {
      "nct_id": "NCT00546728",
      "title": "The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Paul Heart Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2007-10",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2013-11-08",
      "last_synced_at": "2026-07-24T02:48:10.883Z",
      "location_count": 2,
      "location_summary": "Saint Louis Park, Minnesota • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00546728"
    },
    {
      "nct_id": "NCT07180147",
      "title": "Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Alzheimer Disease (AD)",
        "Cardio Vascular Disease",
        "Mild Cognitive Impairment (MCI)",
        "Frailty Syndrome",
        "Disability Physical",
        "Hypertension",
        "Metabolic Syndrome (MetS)",
        "Healthy Aging",
        "Obesity &Amp; Overweight"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Marymount University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2025-05-01",
      "completion_date": "2031-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-07-24T02:48:10.883Z",
      "location_count": 1,
      "location_summary": "Arlington, Virginia",
      "locations": [
        {
          "city": "Arlington",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07180147"
    },
    {
      "nct_id": "NCT00974272",
      "title": "Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Carl T. Hayden VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "35 Years to 70 Years"
      },
      "enrollment_count": 39,
      "start_date": "2006-08",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2009-09-10",
      "last_synced_at": "2026-07-24T02:48:10.883Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00974272"
    },
    {
      "nct_id": "NCT00099567",
      "title": "Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cognitive Decline"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "70 Years to 79 Years"
      },
      "enrollment_count": 2632,
      "start_date": "1997-01",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2005-11-01",
      "last_synced_at": "2026-07-24T02:48:10.883Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania • Memphis, Tennessee",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00099567"
    },
    {
      "nct_id": "NCT06507722",
      "title": "Night Owl Metabolism",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "PreDiabetes",
        "Overweight",
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Timing of OGTT",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Timing of Standardized Meal",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST",
        "BEHAVIORAL"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "23 Years",
        "sex": "ALL",
        "summary": "18 Years to 23 Years"
      },
      "enrollment_count": 70,
      "start_date": "2025-02-25",
      "completion_date": "2030-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-07-24T02:48:10.883Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06507722"
    },
    {
      "nct_id": "NCT03819153",
      "title": "A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (semaglutide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3533,
      "start_date": "2019-06-17",
      "completion_date": "2024-01-09",
      "has_results": true,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-07-24T02:48:10.883Z",
      "location_count": 117,
      "location_summary": "Tuscumbia, Alabama • Chula Vista, California • Concord, California + 95 more",
      "locations": [
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03819153"
    },
    {
      "nct_id": "NCT02940873",
      "title": "Hypoglycaemia Awareness Restoration Programme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "HARPdoc courses",
          "type": "BEHAVIORAL"
        },
        {
          "name": "BGAT courses",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "King's College London",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 99,
      "start_date": "2017-03-09",
      "completion_date": "2021-04-27",
      "has_results": false,
      "last_update_posted_date": "2021-09-02",
      "last_synced_at": "2026-07-24T02:48:10.883Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02940873"
    },
    {
      "nct_id": "NCT01068860",
      "title": "To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus",
        "Impaired Glucose Tolerance"
      ],
      "interventions": [
        {
          "name": "Canakinumab 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Canakinumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 246,
      "start_date": "2010-02",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2011-09-05",
      "last_synced_at": "2026-07-24T02:48:10.883Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Santa Ana, California • Spring Valley, California + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Spring Valley",
          "state": "California"
        },
        {
          "city": "Madisonville",
          "state": "Kentucky"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01068860"
    }
  ]
}